MESO — MESOBLAST LTD
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1345099 ·
Last close
$11.91
Market Cap
$1.55B
52W High
$21.50
52W Low
$11.74
ADV30
271,903
Next earnings
2026-08-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | — | — | — | — | 773,079,000 | 47,390,000 | 204,674,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 782,307,000 | 129,573,000 | 207,623,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,068,403,000
Inventory
$28,111,000
Receivables
$57,660,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$120,250,000
EBITDA
$-44,605,000
Free Cash Flow
$-51,976,248
Enterprise Value
$2,038,132,864
Total Cash
$102,914,000
Total Debt
$127,334,000
Shares Out
129,854,878
Trailing EPS
$-0.44
Book Value
$4.38
ROE
-9.9%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 120,250,000 | -51,250,000 | -57,500,000 | 773,079,000 | 204,674,000 | 568,405,000 | — |
| Jun 2025 | 17,198,000 | -62,443,000 | -102,142,000 | 784,683,000 | 187,241,000 | 597,442,000 | -49,954,000 |
| Jun 2024 | 5,902,000 | -56,224,000 | -87,956,000 | 669,153,000 | 188,798,000 | 480,355,000 | -48,458,000 |
| Jun 2023 | 7,501,000 | -69,289,000 | -81,889,000 | 669,415,000 | 167,577,000 | 501,838,000 | -63,269,000 |
| Jun 2022 | — | — | — | — | — | — | -65,782,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.46
Max Pain — expiry 2028-01-21
max pain strike: $8.00 · spot: $11.64 · call oi: 16,343 · put oi: 167
Expected Move to 2028-01-21:
±$8.12
(69.80%) —
implied range
$3.52 –
$19.77
· ATM straddle on $12.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.56B | $4.37 | — |
| VIR | Vir Biotechnology, Inc. | $1.58B | $9.25 | — |
| LYCA | Lycia Therapeutics, Inc. | $1.61B | $30.92 | — |
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
| IMCR | Immunocore Holdings plc | $1.43B | $27.81 | — |
News headlines (Yahoo Finance, 1h cache)
Mesoblast Showcased at ASX Premier Investor Day Event
2026-11-15 23:16 · Yahoo
Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
2026-11-12 09:12 · Yahoo
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
2026-11-05 00:11 · Yahoo
Our Pick Of The Best Australian Founder Led Stocks In November 2026
2026-11-18 21:11 · Yahoo
Pro Medicus And 2 Other Australian Founder Led Stocks
2026-11-17 20:12 · Yahoo
Top 3 Australian Owner Operator Stocks To Watch In November 2026
2026-11-16 19:15 · Yahoo
Top 3 Australian Founder Led Stocks To Watch In November 2026
2026-11-15 12:11 · Yahoo
3 Australian Growth Stocks To Own In November 2026
2026-11-13 23:14 · Yahoo
3 Australian Founder Led Stocks With Revenue Growth Up To 38%
2026-11-13 07:13 · Yahoo
3 Australian Healthcare Stocks With Earnings Growth Over 21%
2026-11-12 20:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.